---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Special populations"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Special populations. Topics: Age range studied: ARCHER II, Age range studied: ARCHER, Age range studied: phase I glaucoma studies, Age of enrolled participants: ARCHER and ARCHER II, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/special-populations"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Special populations

<a id="heading-2.1.2.8"></a>

## 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

### Age range studied: ARCHER II

> “50 Years and older (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT06510816](https://clinicaltrials.gov/study/NCT06510816)

<a id="topic-2.1.2.8-2"></a>

### Age range studied: ARCHER

> “50 Years and older (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-2.1.2.8-3"></a>

### Age range studied: phase I glaucoma studies

> “In the phase Ia study, eligible patients were aged ≥ 18 years”
> “In the phase Ib study, eligible patients were aged ≥ 18 years”
> “The mean age overall was 70 years in phase Ia and 68 years in phase Ib.”

Source: [Sun et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10130689/)

<a id="topic-2.1.2.8-4"></a>

### Age of enrolled participants: ARCHER and ARCHER II

| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
| --- | --- | --- |
| Age, mean (SD) | “80.0 (8.2)” | “78.4 (8.0)” |

Source: [Abbey (2026)](https://annexonbio.com/wp-content/uploads/2026/09/910_Friday_Abbey_Baseline-Characteristics-of-Participants-in-the-Phase-3-ARCHER-II-Trial-in-Dry-AMD-With-GA-FINAL-25Sept26.pdf)

<a id="topic-2.1.2.8-5"></a>

### Pregnancy, breastfeeding, and contraception: ARCHER eligibility criterion

> “A female participant is eligible if she is not pregnant or breastfeeding and is a woman of non-childbearing potential or is using a contraceptive method that is highly effective, with a failure rate of <1% during the study intervention period and for at least 30 days after the last dose of study intervention.”

Source: [ClinicalTrials.gov NCT04656561](https://clinicaltrials.gov/study/NCT04656561)

<a id="topic-2.1.2.8-6"></a>

### Pediatric use, renal impairment, and hepatic impairment

No evidence found.

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
